LONDON, July 21 (UPI) -- A British clinical trial of HIV vaccine demonstrates an approximately 90 percent difference in viral count in HIV-infected people, researchers say.
Gregory Stoloff, chief executive officer of Seek -- a privately owned biopharmaceutical company -- said this is the first time ever that a human immunodeficiency virus vaccine has shown such a meaningful result in a human clinical trial.